These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22384257)

  • 21. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
    Schmitt NC; Trivedi S; Ferris RL
    Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new gamboge derivative compound 2 inhibits cancer stem-like cells via suppressing EGFR tyrosine phosphorylation in head and neck squamous cell carcinoma.
    Deng R; Wang X; Liu Y; Yan M; Hanada S; Xu Q; Zhang J; Han Z; Chen W; Zhang P
    J Cell Mol Med; 2013 Nov; 17(11):1422-33. PubMed ID: 24112466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.
    Maseki S; Ijichi K; Tanaka H; Fujii M; Hasegawa Y; Ogawa T; Murakami S; Kondo E; Nakanishi H
    Br J Cancer; 2012 Mar; 106(6):1196-204. PubMed ID: 22315058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
    Ma L; Zhang G; Miao XB; Deng XB; Wu Y; Liu Y; Jin ZR; Li XQ; Liu QZ; Sun DX; Testa JR; Yao KT; Xiao GH
    FEBS J; 2013 May; 280(9):2027-41. PubMed ID: 23461856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Nanbu T; Umemura N; Ohkoshi E; Nanbu K; Sakagami H; Shimada J
    Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells.
    Bourguignon LY; Gilad E; Brightman A; Diedrich F; Singleton P
    J Biol Chem; 2006 May; 281(20):14026-40. PubMed ID: 16565089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.
    Zhang M; Piao L; Datta J; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
    Mol Cancer Ther; 2015 Oct; 14(10):2313-20. PubMed ID: 26227488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma.
    Bourguignon LY; Wong G; Shiina M
    J Biol Chem; 2016 May; 291(20):10571-85. PubMed ID: 27002147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
    Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA
    J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.
    Nguyen KA; Keith MJ; Keysar SB; Hall SC; Bimali A; Jimeno A; Wang XJ; Young CD
    Mol Carcinog; 2022 Jul; 61(7):664-676. PubMed ID: 35417043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
    Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
    Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
    Brands RC; Müller-Richter UD; De Donno F; Seher A; Mutzbauer G; Linz C; Kübler AC; Hartmann S
    Mol Med Rep; 2016 Mar; 13(3):2338-44. PubMed ID: 26782932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.
    Sriuranpong V; Park JI; Amornphimoltham P; Patel V; Nelkin BD; Gutkind JS
    Cancer Res; 2003 Jun; 63(11):2948-56. PubMed ID: 12782602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.